High Note Wealth’s Biogen BIIB Stock Holding History

High Note Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.3K	Buy	105 +9	+9%	+$1.66K	﹤0.01%	279
2025 Q4	$16.9K	Sell	96 -3	-3%	-$490	﹤0.01%	281
2025 Q3	$13.9K	Buy	99 +64	+183%	+$8.65K	﹤0.01%	284
2025 Q2	$4.4K	Hold	35	–	–	﹤0.01%	480
2025 Q1	$4.79K	Sell	35 -22	-39%	-$3.15K	﹤0.01%	429
2024 Q4	$8.68K	Buy	+57	New	+$9.61K	﹤0.01%	312
2021 Q4	–	Sell	-6,766	Closed	-$1.91M	–	85
2021 Q3	$1.91M	Buy	6,766 +11	+0.2%	+$3.6K	0.69%	42
2021 Q2	$2.34M	Sell	6,755 -69	-1%	-$20.9K	0.85%	41
2021 Q1	$1.91M	Buy	6,824 +235	+4%	+$63.4K	0.74%	44
2020 Q4	$1.61M	Buy	+6,589	New	+$1.7M	0.69%	45

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

High Note Wealth's BIIB Position: Q1 2026 in Review

High Note Wealth increased its Biogen (BIIB) stake by 9.4% in Q1 2026, buying an estimated $1.66K and bringing the position to 105 shares worth $19.3K. The position accounts for ﹤0.01% of the portfolio, ranked #279.

High Note Wealth first reported a position in BIIB in Q4 2020 and has held it in 10 quarters since. The position peaked at $2.34M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

High Note Wealth held 105 shares of Biogen worth $19.3K as of Q1 2026.
High Note Wealth bought 9 Biogen shares in Q1 2026, an estimated $1.66K.
Biogen made up ﹤0.01% of High Note Wealth's portfolio in Q1 2026, its #279 holding.
High Note Wealth first reported a position in Biogen in Q4 2020 and has held it in 10 quarters since.
High Note Wealth's Biogen position peaked at $2.34M in Q2 2021.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on High Note Wealth's 13F filing for Q1 2026, filed 11 May 2026.